|
News
CritiTech Shows Small Particle Success
August 31, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech announced today that it has entered
into an agreement to perform feasibility studies for the development
of nano/micro particle compounds with a major international
pharmaceutical company. Previously, CritiTech has successfully
produced small particle compounds for this company.
“We are encouraged by the continued
interest and support demonstrated by this major company in
using CritiTech’s proprietary technology to help solve
some of their drug delivery and development challenges,”
said CEO and President Sam Campbell.
With the establishment of its new research
and commercial lab facility located at 4950 Research Park
Way, Lawrence, Kansas, CritiTech intends to expand its outreach
to the pharmaceutical industry to help address their drug
delivery and development needs. CritiTech has successfully
performed feasibility work for other pharmaceutical companies
and currently has several ongoing projects.
CritiTech provides critical drug delivery
and development technology for the pharmaceutical industry.
CritiTech produces fine-particle pharmaceuticals including
nanoparticle pharmaceuticals using patented technologies developed
at the University of Kansas. The processes use compressed
carbon dioxide as the processing medium to produce relatively
residue-free and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited
substantial interest in processes that produce improved formulations
using nanoparticulate drugs in order to extend the patent
life of an existing drug or to enable the delivery of a poorly
soluble compound. CritiTech has also successfully used its
proprietary technology to coat medicinal agents either on
small particle drugs for improved drug delivery or as a thin
film on implantable medical devices such as cardiac stents.
The Nanotax™ ovarian cancer drug is the first drug to
be announced under the company’s drug development program.
|
